ADVFN Logo ADVFN

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.
Editas Medicine Inc

Editas Medicine Inc (EDIT)

1.84
-0.02
(-1.08%)
Al cierre: 26 Febrero 3:00PM
1.85
0.01
( 0.54% )
Fuera de horario: 5:20PM
Gráfico avanzado

Discusiones en tiempo real e ideas comerciales: opere con confianza con nuestra poderosa plataforma.

Estadísticas y detalles clave

Último Precio
1.85
Postura de Compra
1.84
Postura de Venta
1.87
Volume Operado de la Acción
1,744,799
1.82 Rango del Día 1.9499
1.12 Rango de 52 semanas 11.58
Capitalización de Mercado [m]
Precio Anterior
1.86
Precio de Apertura
1.89
Última hora de negociación
17:14:50
Volumen financiero
US$ 3,263,891
Precio Promedio Ponderado
1.8706
Volumen promedio (3 m)
4,151,490
Acciones en circulación
82,548,099
Rendimiento del Dividendo
-
Ratio Precio/Utilidad
-1.00
Beneficio por acción (BPA)
-1.86
turnover
78.12M
Beneficio neto
-153.22M

Acerca de Editas Medicine Inc

Editas Medicine Inc is a gene-editing company. It is engaged in treating patients with genetically defined diseases by correcting disease-causing genes. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR... Editas Medicine Inc is a gene-editing company. It is engaged in treating patients with genetically defined diseases by correcting disease-causing genes. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company's only operating segment is developing and commercializing genome editing technology. Mostrar más

Sector
Biological Pds,ex Diagnstics
Industria
Biological Pds,ex Diagnstics
Sede
Wilmington, Delaware, USA
Fundado
-
Editas Medicine Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker EDIT. The last closing price for Editas Medicine was US$1.86. Over the last year, Editas Medicine shares have traded in a share price range of US$ 1.12 to US$ 11.58.

Editas Medicine currently has 82,548,099 shares in issue. The market capitalisation of Editas Medicine is US$153.54 million. Editas Medicine has a price to earnings ratio (PE ratio) of -1.00.

EDIT Últimas noticias

Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
1-0.01-0.5376344086021.863.29991.75172862442.68892366CS
40.4431.20567375891.413.29991.1263469202.32947725CS
12-0.12-6.091370558381.973.29991.1241514901.92476354CS
26-2.05-52.56410256413.94.121.1229946282.42151034CS
52-5.82-75.88005215127.6711.581.1224963873.90723338CS
156-14.95-88.988095238116.821.5951.1220053527.94797737CS
260-20.62-91.76680017822.4799.951.12183812820.23329341CS

EDIT - Preguntas Frecuentes

¿Cuál es el precio actual de las acciones de Editas Medicine?
El precio actual de las acciones de Editas Medicine es US$ 1.85
¿Cuántas acciones de Editas Medicine están en circulación?
Editas Medicine tiene 82,548,099 acciones en circulación
¿Cuál es la capitalización de mercado de Editas Medicine?
La capitalización de mercado de Editas Medicine es USD 153.54M
¿Cuál es el rango de negociación de 1 año para el precio de las acciones de Editas Medicine?
Editas Medicine ha negociado en un rango de US$ 1.12 a US$ 11.58 durante el último año
¿Cuál es el ratio PE (precio/beneficio) de Editas Medicine?
El ratio precio/beneficio de Editas Medicine es -1
¿Cuál es el ratio de efectivo a ventas de Editas Medicine?
El ratio de efectivo a ventas de Editas Medicine es 1.95
¿Cuál es la moneda de reporte de Editas Medicine?
Editas Medicine presenta sus resultados financieros en USD
¿Cuál es el último ingresos anual de Editas Medicine?
El último ingresos anual de Editas Medicine es USD 78.12M
¿Cuál es el último beneficio anual de Editas Medicine?
El último beneficio anual de Editas Medicine es USD -153.22M
¿Cuál es la dirección registrada de Editas Medicine?
La dirección registrada de Editas Medicine es 1209 ORANGE STREET, NEW CASTLE, WILMINGTON, DELAWARE, 19801
¿Cuál es la dirección del sitio web de Editas Medicine?
La dirección del sitio web de Editas Medicine es www.editasmedicine.com
¿En qué sector industrial opera Editas Medicine?
Editas Medicine opera en el sector BIOLOGICAL PDS,EX DIAGNSTICS

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
ULYUrgent ly Inc
US$ 0.8668
(106.38%)
6.31M
CPOPPop Culture Group Company Ltd
US$ 1.36
(96.53%)
9.29M
BLMZBloomZ Inc
US$ 0.4997
(38.88%)
6.87M
NIXXNixxy Inc
US$ 2.10
(32.91%)
7.92M
ROOTRoot Inc
US$ 121.00
(22.58%)
118.53k
DMRCDigimarc Corporation
US$ 20.01
(-26.00%)
39.81k
SYTASiyata Mobile Inc
US$ 3.19
(-23.50%)
495.68k
TNDMTandem Diabetes Care Inc
US$ 27.20
(-19.02%)
310.54k
CLEUChina Liberal Education Holdings Ltd
US$ 0.0605
(-18.57%)
7.13M
SPGCSacks Parente Golf Inc
US$ 0.5997
(-18.08%)
1.52M
NVDANVIDIA Corporation
US$ 131.00
(-0.21%)
41.88M
CPOPPop Culture Group Company Ltd
US$ 1.36
(96.53%)
9.29M
NIXXNixxy Inc
US$ 2.10
(32.91%)
7.92M
CLEUChina Liberal Education Holdings Ltd
US$ 0.0605
(-18.57%)
7.13M
BLMZBloomZ Inc
US$ 0.4997
(38.88%)
6.87M

EDIT Finanzas

Finanzas

EDIT Discussion

Ver más
TrendTrade2016 TrendTrade2016 1 semana hace
EDIT EXPLOSION INTOP CLOSE
👍️0
TrendTrade2016 TrendTrade2016 1 semana hace
EDIT MONSTER
👍️0
TrendTrade2016 TrendTrade2016 1 semana hace
EDIT BEASTING
👍️0
makinezmoney makinezmoney 2 semanas hace
$EDIT: DoubleBottom confirmed on 100day chart...... now 1.35

This is gonna go to $1.60 from here................... take that to the bank.


GO $EDIT
👍 1
Monksdream Monksdream 2 meses hace
EDIT, under $2
👍️0
Monksdream Monksdream 2 meses hace
EDIT, new 52/week low
👍️0
jondoeuk jondoeuk 2 meses hace
Another update https://www.globenewswire.com/news-release/2024/12/12/2996508/0/en/Editas-Medicine-Announces-Strategic-Transition-to-in-vivo-Gene-Editing-Company-with-Intent-to-Achieve-Human-Proof-of-Concept-in-Approximately-Two-Years.html

Any target they go after will likely have multiple players (far) ahead them (and some using better delivery and/or editing tech).
👍️0
Monksdream Monksdream 3 meses hace
EDIT, new 52 week low
👍️ 1
jondoeuk jondoeuk 4 meses hace
OT: In this Dr. Urnov, PhD, laid out the urgent case for major reform in the regulatory appraisal of clinical therapies involving CRISPR gene therapies https://www.liebertpub.com/doi/10.1089/crispr.2024.0082
👍️0
jondoeuk jondoeuk 4 meses hace
From the Q&A's, there was no date given on when they will file an IND. They did not answer if other HSC's are targeted. They did not answer what the LNP targeting moiety is. They did not answer how long they will continue to put money into Reni-cel. They did not answer what doses were given. They also said that redosing is being explored (to achieve higher editing efficiency).

I doubt there will be a partner for Reni-cel unless they get a huge part of in vivo as well.
👍️0
jondoeuk jondoeuk 4 meses hace
An update https://www.biospace.com/press-releases/editas-medicine-to-host-strategic-update-webinar-to-detail-progress-towards-2024-goals-including-achievement-of-establishing-in-vivo-preclinical-proof-of-concept

https://www.globenewswire.com/news-release/2024/10/21/2966518/0/en/Editas-Medicine-and-Genevant-Sciences-to-Collaborate-to-Develop-Novel-mRNA-LNP-Gene-Editing-Therapeutics.html
👍️0
Monksdream Monksdream 5 meses hace
EDIT new 52 week low
👍️0
Monksdream Monksdream 5 meses hace
EDIT new 52 weeknlow
👍️0
Monksdream Monksdream 6 meses hace
EDIT new 52 low
👍️0
Monksdream Monksdream 6 meses hace
EDIT new 52 week low
👍️0
Monksdream Monksdream 6 meses hace
EDIT under $4
👍️0
Monksdream Monksdream 6 meses hace
EDIT new 52 low
👍️0
Monksdream Monksdream 6 meses hace
EDIT new 52 week high
👍️0
Monksdream Monksdream 7 meses hace
EDIT new 52. Week low
👍️0
Monksdream Monksdream 7 meses hace
EDIT under $6
👍️0
Monksdream Monksdream 8 meses hace
EDIT under $5
👍️0
Monksdream Monksdream 8 meses hace
EDIT new 52 week low
👍️0
Monksdream Monksdream 8 meses hace
EDIT new 52 week low
👍️0
Monksdream Monksdream 8 meses hace
EDIT new 52 week low
👍️0
jondoeuk jondoeuk 8 meses hace
Looking at HbF levels, EDIT-301 appears to achieve slightly higher levels than Casgevy. For total Hb levels, EDIT-301 seems to outperform Casgevy https://finance.yahoo.com/news/editas-medicine-announces-safety-efficacy-070000921.html

However, the ongoing trials and launch are going to be costly, and they aren't working on busulfan free conditioning.
👍️0
Monksdream Monksdream 9 meses hace
EDIT under $10
👍️0
jondoeuk jondoeuk 9 meses hace
(OT): A new AI paper from Princeton and Stanford https://www.biorxiv.org/content/10.1101/2024.04.25.591003v2.full

CRISPR-GPT demonstrated a marked improvement in gene-editing experiments, increasing the accuracy of target gene modifications by up to 30% compared to conventional methods. In validation tests, it achieved a specificity rate exceeding 95%, with a significant reduction in off-targets. The system also reduced the time required to design and plan experiments by approximately 40%, streamlining the workflow for researchers
👍️0
jondoeuk jondoeuk 10 meses hace
Dr. Liu moved on with base and prime editing and just left the company to die on the vine.
👍️0
Monksdream Monksdream 10 meses hace
EDIT under $10
👍️0
Monksdream Monksdream 10 meses hace
EDIT new 52 week low
👍️0
Monksdream Monksdream 10 meses hace
EDIT new 52 lo

👍️0
Monksdream Monksdream 10 meses hace
EDIT new 52 lo
👍️0
jondoeuk jondoeuk 2 años hace
Could be upcoming https://annualmeeting.asgct.org/program/agenda-details?agendaId=25899

If so, CRSP and NTLA have already disclosed preclinical data for in vivo editing.
👍️0
jondoeuk jondoeuk 2 años hace
Does this have any FDA approvals?

No. Plus they are currently focusing on TDT and SCD, both early stage, and both indications becoming more crowed. Also, CRSP should get FDA and EMA approvals for exa-cel in those indications and should have at least five years head start over others.

Will Precision Biosciences be this high or higher?

If the clinical data they present in April/May is good, I expect the SP will increase, but not as high as this. They (DTIL) will also have an upcoming R&D Day (focusing on in vivo programs) mid-year.

How do the two compare?

There are a number of differences. One example, DTIL have yet to show they can do in vivo editing in humans. Another, both have broad plans for in vivo programs, but delivery outside the liver (using current AAVs for many indications) can be problematic.
👍️0
rtrstock rtrstock 2 años hace
Does this have any FDA approvals? Will Precision Biosciences be this high or higher? How do the two compare?
👍️0
jondoeuk jondoeuk 3 años hace
PR https://www.globenewswire.com/news-release/2022/05/18/2445810/0/en/Editas-Medicine-Presents-Data-on-SLEEK-Gene-Editing-Technology-at-the-American-Society-of-Gene-and-Cell-Therapy-Annual-Meeting.html

Posters https://www.editasmedicine.com/wp-content/uploads/2022/05/ASGCT2022-EDIT-103-Liu-Presentation.pdf

https://www.editasmedicine.com/wp-content/uploads/2022/05/ASGCT-2022-SLEEK-Zuris.pdf

https://www.editasmedicine.com/wp-content/uploads/2022/05/ASGCT-Kahn-EDIT202-Poster.pdf

https://www.editasmedicine.com/wp-content/uploads/2022/05/ASGCT-Duke-EDIT-101-Immunogenicity-Oral-Presentation.pdf
👍️0
jondoeuk jondoeuk 3 años hace
1106: EDIT-202, a Multiplexed CRISPR-Cas12a Gene-Edited iPSC-Derived NK Cell Therapy Has Prolonged Persistence, Promotes High Cytotoxicity, and Enhances In Vivo Tumor Killing https://annualmeeting.asgct.org/abstracts/abstract-details?abstractId=2005

831: SLEEK: A Method for Highly Efficient Knock-in and Expression of Transgene Cargos for Next-generation Cell-based Medicines https://annualmeeting.asgct.org/abstracts/abstract-details?abstractId=1751
👍️0
jondoeuk jondoeuk 3 años hace
ASGCT title:

EDIT-202, a Multiplexed CRISPR-Cas12a Gene-Edited iPSC-Derived NK Cell Therapy Has Prolonged Persistence, Promotes High Cytotoxicity, and Enhances In Vivo Tumor Killing.
👍️0
jondoeuk jondoeuk 3 años hace
PR https://www.bloomberg.com/press-releases/2022-04-08/editas-medicine-reports-engineered-ink-cell-preclinical-data-at-american-association-for-cancer-research-annual-meeting

Poster https://www.editasmedicine.com/wp-content/uploads/2022/04/AACR_2022_Poster_FINAL.pdf
👍️0
jondoeuk jondoeuk 3 años hace
AACR abstract

AsCas12a gene-edited iPSC-derived NK cells constitutively expressing CD16 and membrane-bound IL-15 demonstrate prolonged persistence and robust anti-tumor activities in a solid tumor mouse model https://www.abstractsonline.com/pp8/#!/10517/presentation/16690
👍️0
jondoeuk jondoeuk 3 años hace
ASH PR https://www.globenewswire.com/news-release/2021/12/12/2350352/0/en/Editas-Medicine-Reports-Preclinical-Data-Demonstrating-Robust-Tumor-Reduction-and-Clearance-Using-Novel-Engineered-iNK-Cells-at-the-American-Society-of-Hematology-Annual-Meeting.html

Poster https://www.editasmedicine.com/wp-content/uploads/2021/12/ASH_2021_iNK_poster_presentation.pdf
👍️0
jondoeuk jondoeuk 3 años hace
From the PR: In these experiments, iPSCs were edited using the Company’s SLEEK gene editing technology at the GAPDH locus with a proprietary, Editas-engineered AsCas12a nuclease to knock-in high-affinity CD16 and membrane bound IL-15. iPSC clones were then differentiated into iNKs that were confirmed to express high levels of CD16 and IL-15. Increasing NK cell CD16 expression can improve anti-tumour activity when combined with antibody-dependent cell-mediated cytotoxicity (ADCC)-enabling antibodies. IL-15 is important for NK cell survival, and increasing IL-15 expression prolongs the persistence of NK cells. Knock-in of IL-15 may also eliminate the need to administer cytokines systemically, which can cause severe toxicity.

Results demonstrated that the edited iNK cells exhibited enhanced serial tumour cell killing through ADCC in a2D assay against SKOV-3 ovarian cancer cells and in a 3D tumour spheroid killing assay. The edited iNK cells were also able to persist for a dramatically longer period of time relative to unedited iNK cells. Together, these data provide strong support for the continued development of engineered iPSC derived iNK cells as a potential novel class of therapeutics targeting solid tumours.

''In this promising new research, we demonstrate the use of our proprietary SLEEK technology to knock-in both CD16 and IL-15 into iNK cells. The engineered cells demonstrated potent anti-tumour activity and substantially increased persistence without systemic cytokines, an important limitation with many existing NK cell approaches. We also believe this to be a potentially safer and more reliable approach to developing next generation NK cell therapy medicines because through our iPSC development process, we only select cell clones that have exactly the desired on-target edits, thereby avoiding the possibility of cell abnormalities being introduced,'' said Mark S. Shearman, Ph.D., Executive Vice President and Chief Scientific Officer, Editas Medicine. ''NK cells are great candidates for off-the-shelf immunotherapy medicines given their high tumour killing capacity and their low propensity for graft-versus-host disease, and we believe these data provide evidence for the potential of future experimental medicines from our iNK program to exert enhanced anti-tumour activity in the clinic in the treatment of solid tumours.''
👍️0
jondoeuk jondoeuk 3 años hace
SITC poster https://www.editasmedicine.com/wp-content/uploads/2021/11/SITC_2021_CD16mbIL-15_KI_iNKs_poster_FINALv.pdf
👍️0
jondoeuk jondoeuk 3 años hace
ASH abstracts

Deletion of CISH and TGFßR2 in iPSC-Derived NK Cells Promotes High Cytotoxicity and Enhances In Vivo Tumor Killing https://ash.confex.com/ash/2021/webprogram/Paper150731.html

Preclinical Development of EDIT301, an Autologous Cell Therapy Comprising AsCas12a-RNP Modified Mobilized Peripheral Blood-CD34+ Cells for the Potential Treatment of Transfusion Dependent Beta Thalassemia https://ash.confex.com/ash/2021/webprogram/Paper149956.html
👍️0
IH Market Vision [Andrew] IH Market Vision [Andrew] 3 años hace
GRTS and EDIT Biotech Stock Plays Update | Big Events Coming Up!

I chat about some recent events and news with Gritstone ($GRTS) and Editas ($EDIT) - two very exciting biotechnology companies doing work in a variety of treatments like immunotherapy & gene editing.



Watch on YouTube
👍️0
jondoeuk jondoeuk 3 años hace
Initial clinical data for 101 is planned later this month. The data will include patient safety assessments and a preliminary analysis of secondary endpoints relating to signals of gene editing and clinical benefit. The presentation will cover cumulative data from patients in the adult low-dose and mid-dose cohorts. As required by the trial protocol, all patients are monitored every three months for the first year and at various timepoints for another two years.
👍️0
IH Market Vision [Andrew] IH Market Vision [Andrew] 4 años hace
Editas ($EDIT) has a Big Event Coming Up! | Gene Editing Biotech

Editas ($EDIT) has got a big event on September 27th, and I decided to ride the wave and share my thoughts as to why. Events are king in biotechs. Tell us what you think about our new series! Is this the kind if info you would be looking for? What other DD should we add?

Watch the Video on Youtube



👍️0
Scott 75 Scott 75 4 años hace
Thank you for the explanation and your time. Have a good weekend.
👍️0
jondoeuk jondoeuk 4 años hace
Cancer is highly complex, so multiplexed gene editing will be needed to generate better cell therapies. One of the benefits of CRISPR is the ability to knockout multiple genes with (very) high efficacy, but that has not been the case for knock-ins. Now with this approach, it seems to have been overcome. If you take HLA-E, the efficacy (for knock-in) was over 88%, and this should 'shield' the majority of cells from being rejected by the patient they would be given to. ADAP will use the same approach for its iPSC-derived TCR-T cell therapies https://www.nature.com/articles/nbt.3860
👍️0
Scott 75 Scott 75 4 años hace
Wow that sounds so?? What the heck does any of that mean?
👍️0

Su Consulta Reciente

Delayed Upgrade Clock